n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, August 2nd, 2017

The QualityStocks
Daily Stock List

graphic
graphic

U3O8 Corp. (UWEFF)

InvestorIntel and Streetwise Reports reported earlier on U3O8 Corp. (UWEFF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

U3O8 Corp. concentrates on the exploration and development of deposits of uranium and associated commodities in South America. The Company's mineral resources estimates were made in accordance with National Instrument 43-101 (NI-43-101). They are contained in three deposits. U3O8 is based in Toronto, Ontario, and the Company’s shares trade on the OTC Markets Group’s OTCQB.

Concerning the three deposits, one is the Laguna Salada Deposit, Argentina. A Preliminary Economic Assessment (PEA) shows this near surface, free-digging uranium-vanadium deposit has low production-cost potential.

A second deposit is the Berlin Deposit, Colombia. A PEA shows that Berlin has low-cost uranium production potential due to revenue that would be produced from by-products of phosphate, vanadium, nickel, rare earths (yttrium and neodymium) and other metals, which occur within the deposit. Potential by-products from uranium production include commodities used in the energy storage industry, in the making of batteries, including nickel, vanadium, and phosphate.

A third deposit is the Kurupung Deposit, Guyana. Here, a uranium resource has been estimated in four veins within a uranium-zirconium vein system. Resources have been estimated on four veins. Consistent mineralization of the same type has been intersected in scout drilling of an additional six veins, while yet other veins require initial exploration drilling.

In late June 2017, U3O8 announced terms of the financing available to its existing shareholders. The Company seeks to raise $250,000 via the sale of 10 million Units priced at 2.5c per Unit.

U308 wants to raise funds to refine and optimize metallurgical test work on the Laguna Salada Deposit, centered on pushing down estimated production costs, and for general administrative purposes. Furthermore, it wants to provide existing shareholders with an opportunity to cost-effectively increase their shareholding in U308 before the capital restructuring, which was approved by shareholders at its Annual and Special Meting that took place on June 22, 2017.

U3O8 Corp. (UWEFF), closed Wednesday's trading session at $0.02, up 4.71%, on 248 volume with 3 trades. The average volume for the last 60 days is 70,685 and the stock's 52-week low/high is $0.0122/$0.0421.

Tapinator, Inc. (TAPM)

Marketbeat, TopPennyStockMovers, Pennybuster, and TheMicrocapNews reported earlier on Tapinator, Inc. (TAPM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Established in 2013, Tapinator, Inc. is a developer and publisher of mobile games on the iOS, Google Play, and Amazon platforms. The OTCQB-listed Company generates revenues through the sale of branded advertisements, paid downloadable games, and premium in-game content. An emerging mobile gaming leader, Tapinator is based in New York, New York. It has product development teams in the U.S., Canada, Germany, Pakistan, Indonesia, and Russia. The Company has 10 employees and 40 contractors.

Tapinator was founded by a team that has been working together to build mobile games and applications since 2007. Mr. Ilya Nikolayev is the Company’s Chief Executive Officer (CEO). Mr. Nikolayev is an accomplished technology executive. He previously served as the CEO and Co-Founder of Familybuilder.

Mr. Nikolayev created one of the first successful Facebook applications, Family Tree, in 2007, and grew the property to more than 6 million monthly active unique users and 45 million total users. Tapinator and Mr. Nikolayev were earlier featured prominently in profiles conducted by Huffington Post and Forbes. Tapinator has a veteran management team/Board with high-growth and large internet company credentials and a record of accomplishment building successful digital media businesses.

Tapinator's portfolio comprises more than 300 mobile gaming titles which, collectively, have attained greater than 400 million player downloads. This includes games such as ROCKY™, Combo Quest, Video Poker Classic, Solitaire Dash, and Burn It Down.

This past May, Tapinator announced the launch of three new social casino and card game properties within the foremost mobile app stores. These properties are Solitaire Dash on iOS, Google Play, and Amazon; Deuces Wild Classic on iOS, Google Play, and Amazon; and Double Double Bonus Poker Classic on iOS, Google Play, and Amazon.

Solitaire Dash is Tapinator’s first solitaire property. Deuces Wild Classic is a spinoff from the Company’s flagship Video Poker Classic product that features 39 authentic game variants. Double Double Bonus Poker Classic is a second spinoff from Tapinator's flagship Video Poker Classic. It targets players of Double Double Bonus.

Tapinator has a two-pronged business strategy. One is to produce a large number of “Rapid-Launch Games” that have low development costs and predictable returns. The second is to produce a select number of original “Full-Featured Games” that have higher development costs yet offer significant upside. Of note is that 66 percent of the Company’s games older than 180 days are profitable.

Tapinator, Inc. (TAPM), closed Wednesday's trading session at $0.118, up 2.61%, on 72,105 volume with 23 trades. The average volume for the last 60 days is 27,428 and the stock's 52-week low/high is $0.08/$0.29.

BioCardia, Inc. (BCDA)

TradingView and MarketWatch reported on BioCardia, Inc. (BCDA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BioCardia, Inc. is a leader in the development of complete solutions for cardiovascular regenerative therapies. The Company’s biotherapeutic product candidates in clinical development are CardiAMP® (autologous minimally processed bone marrow cells [a patient’s own cells]) and CardiALLO® (allogenic culture expanded mesenchymal stem cells derived from bone marrow [donor-derived]) cell therapies. A clinical-stage regenerative medicine enterprise, BioCardia has its corporate head office in San Carlos, California.

The Company’s two therapeutic programs are enabled by its Helix™ transendocardial delivery systems and Morph® vascular access products that are partnered to enable other promising biotherapeutic programs. In addition, the Helix transendocardial delivery system is being used by a number of clinical partners in biotherapeutic clinical trials.

The Company’s Helix transendocardial delivery system is the top percutaneous catheter delivery system for cardiovascular regenerative medicine. Helix enables the local delivery of cell and gene based therapies to treat heart failure, myocardial infarction, ischemia, as well as cardiac conduction disorders.

BioCardia’s CardiAMP harnesses the potential of autologous minimally processed bone marrow cells, utilizing a companion diagnostic to identify patients most likely to benefit from the therapy. The design of the investigational CardiAMP cell therapy system is to deliver a high dose of a patient’s own bone marrow cells directly to the area of cardiac dysfunction to stimulate the body’s natural healing mechanism after a heart attack.

CardiALLO uses younger universal donor mesenchymal stem cells. The Company states that CardiALLO may be appropriate for patients who are not optimal candidates for the CardiAMP therapy.

Last week, BioCardia announced completion of treatment for the 10-patient roll-in cohort for the pivotal Phase III CardiAMP Heart Failure Trial. A pre-specified review of the 30-day outcomes in the cohort by the Data Safety Monitoring Board is anticipated in Q3 of 2017.

The CardiAMP Heart Failure Trial is a Phase III, multi-center, randomized, double-blinded, sham-controlled study of up to 260 patients at 40 centers across the nation. The trial’s primary endpoint is an improvement in six-minute walking distance at 12 months post-treatment. Additionally, the primary endpoint analysis incorporates the impact of major adverse cardiac events and other clinically meaningful events.

BioCardia’s Chief Medical Officer, Mr. Eric Duckers, MD, PhD, FESC, stated, “Leading clinical sites are actively screening patients for the randomized phase of our Phase III trial, and we are onboarding additional clinical sites in the United States. The company anticipates filing an investigational device exemption (IDE) supplement to add an interim efficacy readout in the fourth quarter of 2018 and expects top line data in the fourth quarter of 2019.”

BioCardia, Inc. (BCDA), closed Wednesday's trading session at $0.575, even for the day, on 17,481 volume with 13 trades. The average volume for the last 60 days is 70,016 and the stock's 52-week low/high is $0.1001/$1.28.

Royale Energy, Inc. (ROYL)

Microcapmillionaires, Jason Bond, Marketbeat, SmarTrend Newsletters, SmallCapVoice, Wall Street Resources, Investing Futures, WealthMakers, Turn Key Oil, Stock Analyzer, and Oakshire Financial reported previously on Royale Energy, Inc. (ROYL), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Royale Energy, Inc. centers on the acquisition, development, and marketing of natural gas and oil. The Company owns and operates wells in the Sacramento and San Joaquin basins in California and in the U.S. Gulf Coast. An independent exploration and production enterprise, Royale engages in the production and sale of natural gas; the acquisition of oil and gas lease interests and proved reserves; the drilling of exploratory and development wells; and the sale of fractional working interests in wells to undergo drilling. Royale Energy is headquartered in El Cajon, California.

The Company has properties covering greater than 20,000 acres in California and nine 3D seismic surveys in the Sacramento Basin. At present, the Company operates more than 60 natural gas wells to date. It owns interests in 12 natural gas fields in California. Royale’s Cardiff well went into production on February 4, 2014.

Royale Energy has acquired over 96,000 acres on the Alaskan North Slope. The acreage spans over 88 miles east and west of the Trans-Alaska pipeline route. Additionally, its Victor Ranch Field is in Tehama County, in the Northern Sacramento Basin. This field has been producing natural gas for Royale since it drilled its first well there in 1993.

Furthermore, Royale’s North Arbuckle is in Colusa County in the Sacramento Basin. Currently, this is the most active area for the Company. It has 10 producing natural gas wells, which have produced in excess of 5 billion cubic ft. The Company’s plan is to drill many more in the next couple of years.

Royale Energy also has its Lonestar Field. It covers more than 1,000 acres. The Lonestar Field has produced over five billion cubic ft. of gas from five separate Forbes sandstone reservoirs. The Lonestar Field includes the Goddard 7-1 Well; the Goddard #2 and Goddard #3 (offset wells to the Goddard 7-1); and the Magnum Well. Moreover, Royale owns non-operated interests in Texas, Louisiana, and Oklahoma.

Royale Energy has an agreement with a major independent exploration and development company to expand its joint development agreement in the Sacramento Basin of Northern California. The expanded arrangement encompasses approximately 1,900 acres in the Rio Vista Gas Field. Royale will target the Capay and Martinez sands, which produce at depths of 4,500’ and 6,000’, respectively.

Royale Energy and privately held Matrix Oil Corp. entered into a Letter of Intent (LOI) to merge in a combined stock and assumption of debt transaction. Royale Energy announced that on February 14, 2017, Royale Energy Holdings, Inc. (Royale Holdings), filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) for a proposed merger between Royale Holdings, Royale, and Matrix Oil Management Corporation and its affiliates. Matrix Oil has oil and gas properties in the Sacramento, San Joaquin, and Los Angeles Basins of California and the Permian Basin of Texas.

Recently, Royale Energy announced it signed a drilling contract for three additional wells in the Rio Vista Field in the Sacramento Basin. The CRC 8-3, the CRC 8-4, and the CRC 8-5 wells will be drilled under the Company’s joint venture (JV) Agreement encompassing the Rio Vista Field. Employing 3-D seismic, Royale Energy and its partner identified a number of prospective locations in the Martinez, McCormick, and Capay formations in the field.

Royale Energy, Inc. (ROYL), closed Wednesday's trading session at $0.386177, down 0.98%, on 11,700 volume with 6 trades. The average volume for the last 60 days is 11,422 and the stock's 52-week low/high is $0.32/$0.94.

Walker Innovation, Inc. (WLKR)

TradingView, Marketbeat, MarketWatch, Seeking Alpha, Wall Street Mover, and Wall Street Journal reported on Walker Innovation, Inc. (WLKR), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Walker Innovation, Inc. is an innovation services enterprise that helps companies improve their internal product and business development efforts. Additionally, the Company owns a portfolio of its own intellectual property (IP). Walker Innovation looks to commercialize, license, as well as enforce the unique portfolio of IP developed by inventor and entrepreneur, Mr. Jay Walker, who serves as Walker Innovation’s Executive Chairman. Mr. Walker is best known as the Founder of Priceline.com.

Walker Innovation was incorporated in the State of Delaware in January 2002. Walker Innovation has its corporate office in Stamford, Connecticut. The Company previously went by the name Patent Properties, Inc. It changed its name to Walker Innovation, Inc. in July of 2015. The Company lists on the OTCQB.

Walker Innovation’s present plan of operations includes the start of an effort to acquire, via merger, share exchange, or other transactions, one or more operating businesses, or control of such operating businesses by way of contractual arrangements. The Company’s Licensing and Enforcement division grants IP rights for the use of or regarding, patented technologies. This division monetizes its IP through the sale of select patent assets.

Walker Innovation’s patent portfolio consists of 400 granted patents, and around 60 pending patent applications. The Licensing and Enforcement division’s patents describe inventions in areas including authentication techniques, Internet search, social networking, advertising, online transactions, and others.

For Q1 2017, Walker Innovation’s Net Loss was reduced by 36 percent to $1.2 million, or $0.06 per share, versus a Net Loss of $1.8 million, or $0.09 per share, in the year-ago period. Operating Expenses decreased by 49 percent to $1.3 million for Q1 of 2017 versus $2.5 million for Q1 of 2016.

This past June, Walker Innovation announced that it raised an additional $16.8 million in funds from agreeing to the redemption of the remainder of its stake in The Upside Commerce Group LLC by Upside. Walker exercised its warrant to acquire 12.65 million shares of Class A Common Stock at a price of $0.06 per share. Upside at the same time redeemed the shares at $1.431 per share, as approved by Walker Innovation’s Audit Committee. Walker expects to use the proceeds to finance its efforts to acquire an operating business, and also its continuing licensing and enforcement operations.

Walker Innovation, Inc. (WLKR), closed Wednesday's trading session at $0.4399, up 4.86%, on 273,146 volume with 29 trades. The average volume for the last 60 days is 51,719 and the stock's 52-week low/high is $0.295/$0.6795.

graphic

The QualityStocks
Company Corner

graphic
graphic

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.40475, off by 1.26%, on 169,076 volume with 59 trades. The stock’s average daily volume over the past 60 days is 78,057 and its 52-week low/high is $0.0913/$0.699.

Lexaria Bioscience Corp. ("the Company") (OTCQB: LXRP) (CSE: LXX), an innovative company licensing proprietary technology for delivery of bioactive compounds including cannabinoids, announces that it has engaged the corporate communications expertise of NetworkNewsWire ("NNW"). "We are excited to be on the cutting-edge of bioscience, developing better ways to deliver health-enhancing cannabinoids to the body," says Lexaria Bioscience CEO and chairman of the board Chris Bunka. "As we continue to fulfil our mission of improving our customers' quality of life through our patented process, we expect our new association with NetworkNewsWire to enhance our initiatives to keep shareholders and potential investors aware of our progress and potential."

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Bioscience Corp. Engages NetworkNewsWire for Corporate Communications Solutions

NetworkNewsWire Announces Publication Highlighting the Operations of Several Public Cannabis-Biotech Companies

Lexaria Bioscience Technology Discussed by CFN Media Cannabis Industry Coverage

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.81, up 12.50%, on 147,340 volume with 60 trades. The stock’s average daily volume over the past 60 days is 36,271 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Introduces Fourth Medical Software Service Line, Continuing Rapid Expansion Strategy

ORHub, Inc. Executing Aggressive Expansion Strategy with Introduction of Third Service Line

ORHub, Inc. Signs National Deployment Agreement to Roll-out Transformative Medical Software in Major U.S. Markets

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.2656, up 3.75%, on 141,611 volume with 113 trades. The stock’s average daily volume over the past 60 days is 370,560, and its 52-week low/high is $0.0501/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Announces Publication in European Journal of Pain

InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media

InMed Signs R&D Agreement with ATERA

Patriot One Technologies, Inc. (PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $0.5949, up 0.83%, on 30,921 volume with 19 trades. The stock’s average daily volume over the past 60 days is 72,270, and its 52-week low/high is $0.4665/$1.49.

Patriot One Technologies, Inc. (PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

NetworkNewsWire Releases Exclusive Audio Interview with Patriot One Technologies, Inc. (PTOTF)

Patriot One Initiates Pacific Rim Sales with Aotea Security of New Zealand

Patriot One Marks 3-Months of Global PATSCAN Sales with $2.7M in Signed Agreements

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0331, off by 19.66%, on 20,991,557 volume with 887 trades. The stock’s average daily volume over the past 60 days is 10,816,179, and its 52-week low/high is $0.0075/$0.142.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsWire Announces Publication Discussing Public Companies Poised to Benefit from Rising Demand for Marijuana

SinglePoint Featured on MoneyTV with Donald Baillargeon, 7/14

NetworkNewsWire Announces Publication Discussing Emerging Standouts in the Legalized Marijuana Sector

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Trader Power News
(MTBC) +34.37%

2.

QualityStocks
(MMTIF) +27.92%

3.

MarketBeat
(SYX) +22.88%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251